NURS 617 / NURS617 Pharmacotherapeutics Review
Final Exam Practice Test Actual 2026/2027 with
Detailed Rationales | 100% Verified | Pass Guaranteed –
A+ Graded
SECTION 1: Pharmacokinetics & Pharmacodynamics (Questions
1–12)
Q1: A patient with chronic kidney disease stage 4 is prescribed a medication
primarily eliminated by renal excretion. Which pharmacokinetic parameter is most
affected in this patient?
A. Absorption
B. Distribution
C. Metabolism
D. Elimination
Correct Answer: D
Rationale: Renal impairment primarily affects drug elimination through reduced
glomerular filtration rate; dose adjustment or extended dosing intervals are required
to prevent drug accumulation and toxicity in patients with decreased renal clearance.
Q2: A drug has a therapeutic index of 2. Which statement best describes the clinical
significance of this value?
,A. The drug has a wide margin of safety between effective and toxic doses
B. The drug requires therapeutic drug monitoring to ensure safety
C. The drug has minimal risk of adverse effects at therapeutic doses
D. The drug can be safely administered without dose adjustment
Correct Answer: B
Rationale: A therapeutic index of 2 indicates a narrow margin between the median
effective dose (ED₅₀) and median lethal dose (LD₅₀); drugs with narrow therapeutic
indices require therapeutic drug monitoring to maintain plasma concentrations
within the narrow therapeutic window.
Q3: A patient taking warfarin is prescribed a new medication that is a strong inhibitor
of CYP2C9. Which effect on warfarin pharmacokinetics is expected?
A. Decreased plasma concentration and decreased anticoagulant effect
B. Increased plasma concentration and increased risk of bleeding
C. No change in plasma concentration but increased receptor sensitivity
D. Increased metabolism and decreased half-life
Correct Answer: B
Rationale: CYP2C9 inhibition decreases warfarin metabolism, leading to increased
plasma concentration, prolonged prothrombin time/INR, and elevated bleeding risk;
dose reduction and frequent INR monitoring are required.
Q4: A drug binds to its receptor and produces a maximal response at 50% receptor
occupancy. Another drug requires 90% receptor occupancy for the same maximal
response. Which pharmacodynamic concept explains this difference?
,A. Potency
B. Efficacy
C. Affinity
D. Intrinsic activity
Correct Answer: A
Rationale: Potency describes the concentration or dose required to produce a given
effect; the drug achieving maximal response at lower receptor occupancy is more
potent, reflecting a higher affinity for the receptor or more efficient signal
transduction.
Q5: A patient receives a loading dose of digoxin followed by a maintenance dose.
The purpose of the loading dose is to:
A. Prevent the development of drug resistance
B. Achieve steady-state plasma concentration rapidly
C. Reduce the frequency of administration
D. Minimize first-pass metabolism
Correct Answer: B
Rationale: A loading dose rapidly achieves the target steady-state plasma
concentration that would otherwise require approximately 5 half-lives to reach with
maintenance dosing alone; this is essential for drugs with long half-lives requiring
rapid therapeutic effect.
Q6: A drug is 90% protein-bound in plasma. Which clinical consequence is most
significant?
, A. The drug has a large volume of distribution
B. Only 10% of the drug is pharmacologically active and available for metabolism
C. The drug crosses the blood-brain barrier easily
D. The drug is rapidly eliminated by the kidneys
Correct Answer: B
Rationale: Highly protein-bound drugs have only the free (unbound) fraction available
for pharmacological activity, distribution, metabolism, and elimination; displacement
by other drugs or decreased albumin can dramatically increase free drug
concentration and toxicity.
Q7: A patient with liver cirrhosis is prescribed a drug with high first-pass metabolism.
Which adjustment is most appropriate?
A. Increase the oral dose to compensate for decreased metabolism
B. Switch to an IV formulation or reduce the oral dose
C. Administer the drug with food to enhance absorption
D. Increase the dosing frequency to maintain therapeutic levels
Correct Answer: B
Rationale: Liver cirrhosis reduces first-pass metabolism, increasing bioavailability of
orally administered drugs; switching to IV formulation or reducing the oral dose
prevents excessive plasma concentrations and potential hepatotoxicity.
Q8: A drug has a half-life of 6 hours. Approximately how long will it take to reach
steady-state plasma concentration with repeated dosing?
Final Exam Practice Test Actual 2026/2027 with
Detailed Rationales | 100% Verified | Pass Guaranteed –
A+ Graded
SECTION 1: Pharmacokinetics & Pharmacodynamics (Questions
1–12)
Q1: A patient with chronic kidney disease stage 4 is prescribed a medication
primarily eliminated by renal excretion. Which pharmacokinetic parameter is most
affected in this patient?
A. Absorption
B. Distribution
C. Metabolism
D. Elimination
Correct Answer: D
Rationale: Renal impairment primarily affects drug elimination through reduced
glomerular filtration rate; dose adjustment or extended dosing intervals are required
to prevent drug accumulation and toxicity in patients with decreased renal clearance.
Q2: A drug has a therapeutic index of 2. Which statement best describes the clinical
significance of this value?
,A. The drug has a wide margin of safety between effective and toxic doses
B. The drug requires therapeutic drug monitoring to ensure safety
C. The drug has minimal risk of adverse effects at therapeutic doses
D. The drug can be safely administered without dose adjustment
Correct Answer: B
Rationale: A therapeutic index of 2 indicates a narrow margin between the median
effective dose (ED₅₀) and median lethal dose (LD₅₀); drugs with narrow therapeutic
indices require therapeutic drug monitoring to maintain plasma concentrations
within the narrow therapeutic window.
Q3: A patient taking warfarin is prescribed a new medication that is a strong inhibitor
of CYP2C9. Which effect on warfarin pharmacokinetics is expected?
A. Decreased plasma concentration and decreased anticoagulant effect
B. Increased plasma concentration and increased risk of bleeding
C. No change in plasma concentration but increased receptor sensitivity
D. Increased metabolism and decreased half-life
Correct Answer: B
Rationale: CYP2C9 inhibition decreases warfarin metabolism, leading to increased
plasma concentration, prolonged prothrombin time/INR, and elevated bleeding risk;
dose reduction and frequent INR monitoring are required.
Q4: A drug binds to its receptor and produces a maximal response at 50% receptor
occupancy. Another drug requires 90% receptor occupancy for the same maximal
response. Which pharmacodynamic concept explains this difference?
,A. Potency
B. Efficacy
C. Affinity
D. Intrinsic activity
Correct Answer: A
Rationale: Potency describes the concentration or dose required to produce a given
effect; the drug achieving maximal response at lower receptor occupancy is more
potent, reflecting a higher affinity for the receptor or more efficient signal
transduction.
Q5: A patient receives a loading dose of digoxin followed by a maintenance dose.
The purpose of the loading dose is to:
A. Prevent the development of drug resistance
B. Achieve steady-state plasma concentration rapidly
C. Reduce the frequency of administration
D. Minimize first-pass metabolism
Correct Answer: B
Rationale: A loading dose rapidly achieves the target steady-state plasma
concentration that would otherwise require approximately 5 half-lives to reach with
maintenance dosing alone; this is essential for drugs with long half-lives requiring
rapid therapeutic effect.
Q6: A drug is 90% protein-bound in plasma. Which clinical consequence is most
significant?
, A. The drug has a large volume of distribution
B. Only 10% of the drug is pharmacologically active and available for metabolism
C. The drug crosses the blood-brain barrier easily
D. The drug is rapidly eliminated by the kidneys
Correct Answer: B
Rationale: Highly protein-bound drugs have only the free (unbound) fraction available
for pharmacological activity, distribution, metabolism, and elimination; displacement
by other drugs or decreased albumin can dramatically increase free drug
concentration and toxicity.
Q7: A patient with liver cirrhosis is prescribed a drug with high first-pass metabolism.
Which adjustment is most appropriate?
A. Increase the oral dose to compensate for decreased metabolism
B. Switch to an IV formulation or reduce the oral dose
C. Administer the drug with food to enhance absorption
D. Increase the dosing frequency to maintain therapeutic levels
Correct Answer: B
Rationale: Liver cirrhosis reduces first-pass metabolism, increasing bioavailability of
orally administered drugs; switching to IV formulation or reducing the oral dose
prevents excessive plasma concentrations and potential hepatotoxicity.
Q8: A drug has a half-life of 6 hours. Approximately how long will it take to reach
steady-state plasma concentration with repeated dosing?
